Despite falling prices and revenue, Shenzhen Bioeasy Biotech...

Despite falling prices and revenue, Shenzhen Bioeasy Biotechnology's high P/S ratio indicates investor optimism. However, if expectations aren't met, the stock may be overpriced. The company's recent revenue decline is concerning, especially compared to the industry's expected 26% growth. The high P/S ratio may not be sustainable if these trends continue.